Veeva Analysts Push Higher as Shorts Keep Covering

Veeva Systems fell 3.1% over the past week to $312.96, a softer outcome than its closest health-tech peers, whose median was roughly flat. Among that group, CERT rose 6.7% and DH gained 3.7%, while DOCS dropped 2.6% and WAY slipped 2.9%, leaving Veeva toward the weaker end of a mixed picture. The short-selling backdrop, though, continues to tighten in the stock's favour. Short interest has fallen 15% over the past seven days to 2.5% of the free float, a level that barely registers as a bearish signal for a $50 billion company. Borrow costs have also eased, to 0.40% annualised, and availability has widened sharply. For every share currently on loan, there are more than 73 available to borrow, up from around 54 a week ago. The borrow market is as relaxed as it has been all year.

The analyst backdrop is more conspicuously bullish than the share price suggests. Barclays raised its target to $375 on October 28, the second time the same analyst lifted the number within a fortnight. Baird moved its target to $350 from $300 on October 26, citing the Q2 results that included 18% revenue growth, 19% billings growth, and a 44.8% non-GAAP operating margin. The consensus mean of $301 sits below where the stock already trades, but the recent direction of travel in individual targets is decisively upward. Bulls point to Vault CRM's expanding footprint across major pharma accounts and accelerating AI product adoption as reasons the market may be underpricing the durable growth runway. The more cautious view centres on a valuation that already reflects a great deal: the stock trades at roughly 31 times earnings, and any softening in Salesforce platform stability or competitive pressure on pricing could erode the premium faster than the growth story can absorb it.

On the insider side, the recent transactions are mostly noise. The General Counsel sold just over $1.5 million worth of shares under a pre-arranged 10b5-1 plan in mid-October, which carries little signal by construction. EVP Daniel Rizzo made a discretionary sale of roughly $1.3 million on October 2. Net insider activity over the past 90 days is negative at around $15 million, but concentrated in planned sales and compensation-related transactions rather than conviction selling. The most notable institutional development is Vanguard's 13G/A filing from March showing its stake falling to zero from 9.4%, a significant change given how large that position was. BlackRock, in contrast, holds 7.9% and added over 1.3 million shares in the most recent quarter.

The print on November 5 will test whether Q3 revenue growth has held close to the 18% pace set in Q2, and whether Vault CRM's customer count continues to expand at a rate that justifies the premium multiple that has rebuilt over the past month.